The $356 Billion Middleman Tax on American Healthcare
In the American healthcare economy, every new layer of bureaucracy arrives with the exact same promise: less waste, lower costs, and better discipline.
The Pharmacy Benefit Manager, or PBM, was introduced to the public in exactly this spirit. Originally designed in the 1960s to process claims and negotiate with drug manufacturers on behalf of employers, PBMs were supposed to be the ultimate consumer advocates. By wielding the collective bargaining power of millions of patients, they would force pharmaceutical companies to offer lower prices.
That was the theory.
Today, the data tells a vastly different story. The PBM is no longer a quiet administrative service; it has mutated into an oligopoly that dictates the terms of American medicine. According to the Drug Channels Institute, three corporate behemoths—CVS Caremark, Express Scripts (owned by Cigna), and OptumRx (owned by UnitedHealth Group)—now process roughly 80 percent of all prescription drug claims in the United States.
They decide which drugs insurance will cover, which pharmacies patients are allowed to use, and which manufacturers get access to millions of insured customers. For years, this industry has defended itself with the language of cost control. But look closely at the mechanics of the modern PBM, backed by recent federal investigations and staggering market data, and you find a system built on five distinct fictions.
The Reality: The PBM revenue model actually incentivizes higher list prices.
The industry’s central argument is that it lowers drug prices by negotiating aggressive rebates from pharmaceutical manufacturers. But this defense ignores a glaring structural flaw: PBM compensation is fundamentally tethered to the drug’s original, inflated sticker price.
Because PBMs negotiate rebates as a percentage of a drug's list price, a higher list price produces a larger rebate. A drug priced at $1,000 with a 40 percent rebate is far more lucrative for a PBM than a drug priced at $500 with no rebate. This dynamic has created what health economists call the "gross-to-net bubble"—the widening gap between the list price of drugs and the net price manufacturers actually keep. In 2024 alone, this bubble of rebates, fees, and discounts hit a staggering $356 billion.
This isn't just an economic theory; it is the basis of massive federal action. In September 2024, the Federal Trade Commission (FTC) sued the "Big Three" PBMs, alleging they intentionally steered patients toward higher-priced insulins specifically because those drugs generated massive rebate payouts. Just two months ago, in February 2026, Express Scripts settled with the FTC in an agreement expected to save patients $7 billion over the next decade.
The Reality: PBMs own the entire playing field.
The word middleman implies neutrality—a referee managing a transaction. But modern PBMs do not stand in the middle; through aggressive vertical integration, they own the game.
CVS Health operates the nation’s largest retail pharmacy chain, the massive health insurer Aetna, and CVS Caremark (handling roughly 27% of all U.S. PBM claims). UnitedHealth Group pairs OptumRx with the largest insurance business in the country. Cigna operates Express Scripts, which ballooned to handling 30% of U.S. claims in 2024.
Once these pieces are combined under a single corporate roof, PBMs are no longer neutral negotiators. They are actively shaping the market, using their leverage to steer patients away from independent pharmacies and into their own highly profitable mail-order or retail subsidiaries.
The Reality: Rebates are pay-to-play fees that patients rarely see.
Rebates are the moral centerpiece of the PBM defense, offered as proof that someone is forcing Big Pharma to give ground. But in reality, rebates function less like discounts and more like toll booths.
Manufacturers pay these rebates to secure favorable placement on a PBM’s "formulary"—the sacred list determining which drugs insurance covers. The drug offering the largest rebate becomes the "preferred" option, even if cheaper, equally effective clinical alternatives exist.
Crucially, these rebates rarely reach the patient at the pharmacy counter. While the PBM and the insurer pocket the negotiated "discount," uninsured patients—and insured patients paying deductibles or coinsurance—are forced to pay out-of-pocket costs based on the artificially inflated list price. The patient absorbs the inflation; the intermediary absorbs the profit.
The Reality: PBMs use network rules to starve independent competitors.
PBMs argue that they manage pharmacy networks to ensure efficiency. But for the thousands of independent pharmacies fighting to stay open, this efficiency is a corporate stranglehold.
PBMs dictate the reimbursement rates pharmacies receive. Frequently, these rates barely cover—and sometimes fall below—the cost of acquiring the drug. Worse, PBMs have historically weaponized "Direct and Indirect Remuneration" (DIR) fees. While a 2024 CMS rule change forced PBMs to move these fees to the point-of-sale, it triggered a devastating "cash flow hangover." Independent pharmacies were suddenly hit with the lowest possible upfront reimbursements in 2024 while simultaneously paying retroactive DIR fees from 2023.
By starving independent competitors through razor-thin margins and predatory fee structures, vertically integrated PBMs ensure a greater reliance on their own dispensing channels.
The Reality: Opacity is a highly profitable shield.
Ask a PBM executive why their pricing structures are so opaque, and the answer is inevitably that the healthcare market is "complicated."
It is complicated, but complexity is highly convenient. Rebates are classified as trade secrets. Contracts are sealed with non-disclosure agreements. Practices like "spread pricing"—where a PBM charges a health plan $100 for a drug, reimburses the pharmacy $20, and quietly pockets the $80 difference—remain invisible without forensic auditing. When the flow of money becomes impossible to follow, accountability disappears.
None of this absolves pharmaceutical manufacturers of their role in the crisis; drug makers still set the initial, often indefensible, prices of medicines. But the PBM demands immediate and severe regulatory scrutiny because it still masquerades as the system’s disciplinarian.
Bipartisan legislative efforts to strictly "delink" PBM profits from drug list prices are a necessary first step. But we must go further. We must aggressively dismantle the anti-competitive vertical integration that allows these entities to self-deal at the expense of public health.
The pharmacy benefit manager was supposed to make the drug market cheaper, clearer, and more rational. Instead, it built a $356 billion shadow economy where prices are opaque, incentives are corrupted, and the middle of the supply chain has quietly become the most profitable place to stand.